ArticleJournal of cachexia, sarcopenia and muscle2020
MT-102 prevents tissue wasting and improves survival in a rat model of severe cancer cachexia.
Article in Journal of cachexia, sarcopenia and muscle, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 24 citations in OpenAlex.
- Pharmacokinetics, Pharmacodynamics and Bioavailability of ACM-001.1 (S-Pindolol Benzoate) in Healthy Volunteers.Journal of cachexia, sarcopenia and muscle · 2025Trial
- Pancreatic cancer cachexia promotes cardiac dysfunction through altered adrenergic signalling in the heart.The Journal of physiology · 2026Article
- Cancer cachexia: molecular basis and therapeutic advances.Signal transduction and targeted therapy · 2026Review
- A comprehensive review of animal models for cancer cachexia: Implications for translational research.Genes & diseases · 2024Review
- Defining and Addressing Research Priorities in Cancer Cachexia through Transdisciplinary Collaboration.Cancers · 2024Review
- Unraveling the lost balance: Adrenergic dysfunction in cancer cachexia.Autonomic neuroscience : basic & clinical · 2024Review
- Cancer-Induced Resting Sinus Tachycardia: An Overlooked Clinical Diagnosis.Oncology reviews · 2024Review
- Pathogenesis, Intervention, and Current Status of Drug Development for Sarcopenia: A Review.Biomedicines · 2023Review
- Effects of S-pindolol in mouse pancreatic and lung cancer cachexia models.Journal of cachexia, sarcopenia and muscle · 2023Article
- The atypical β-blocker S-oxprenolol reduces cachexia and improves survival in a rat cancer cachexia model.Journal of cachexia, sarcopenia and muscle · 2023Article
- The erythropoietin-derived peptide ARA 284 reduces tissue wasting and improves survival in a rat model of cancer cachexia.Journal of cachexia, sarcopenia and muscle · 2022Article
- Short and long-term effect of reproduction on mitochondrial dynamics and autophagy in rats.Heliyon · 2021Article
- Review
- Article
- Muscle Wasting and Sarcopenia in Heart Failure-The Current State of Science.International journal of molecular sciences · 2020Review
- Emerging Strategies Targeting Catabolic Muscle Stress Relief.International journal of molecular sciences · 2020Review
- MT-102 prevents tissue wasting and improves survival in a rat model of severe cancer cachexia.Journal of cachexia, sarcopenia and muscle · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCachexia, a common manifestation of malignant cancer, is associated with wasting of skeletal muscle and fat tissue. In this study, we investigated the effects of a new first in class anabolic catabolic transforming agent on skeletal muscle in a rat model of cancer cachexia.
methodsYoung male Wistar Han rats were intraperitoneally inoculated with 10
resultsThree mg kg
conclusionsThe present study shows that 3 mg kg
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.